French Biopharma Invests in Medidata Technology to Drive Cutting-Edge Cancer and Rare Disease Research

NEW YORK–(BUSINESS WIRE)– Medidata
(NASDAQ: MDSO), the leading global provider of cloud-based solutions for
clinical research in life sciences, today announced that Erytech
Pharma (“Erytech”), a French biopharmaceutical company developing
“tumor starvation” treatments for acute leukemia and other rare oncology
indications, has adopted the Medidata
Clinical Cloud^® platform. Erytech will incorporate
Medidata’s unified solution for randomization and electronic data
capture (EDC) into its Phase I-III clinical trials. By leveraging
Medidata’s cloud technology, Erytech seeks to simplify operational
complexity and maximize scientific insights from its clinical data.

The partnership represents an evolution in Erytech’s clinical operations
strategy, as the company advances its pipeline of novel oncology and
rare disease candidates for patients with unmet medical needs.

“Since Erytech’s inception, our mission has been to challenge aggressive
diseases and improve patients’ lives by investing in the development of
innovative, life-changing therapies,” said Iman El-Hariry, chief medical
officer of Erytech. “Rare blood cancers and other orphan illnesses
require some of the most intricate R&D work, which is why we’ve turned
to a strong technology partner like Medidata to provide us with the
scalable and configurable tools needed to overcome the complexities of
these studies.”

Denise Tilton, Erytech’s head of clinical operations, added: “For many
patients combating these serious and life-threatening conditions, time
is of the essence. Medidata’s unified technology platform allows us to
access clinical data in a timely fashion—increasing the speed and
quality of our R&D programs, and empowering our researchers to continue
pushing the frontiers of rare disease drug development.”

Founded in Lyon, France in 2004, Erytech is dedicated to developing
therapies for patients with unmet medical needs. With a primary focus on
rare blood cancers—including acute lymphoblastic leukemia (ALL) and
acute myeloid leukemia (AML)—and orphan diseases, Erytech is a leader in
the ongoing development of two treatment methodologies: tumor starvation
and drug substance encapsulation in red blood cells. To optimally
support its development pipeline through improved clinical data quality
and efficient randomization and treatment dispension, Erytech is
implementing Medidata’s unified solution for EDC, management and
reporting (Medidata
Rave^®) and trial randomization (Medidata
Balance^®) across its clinical research programs.

“We’re thrilled to be working with such a forward-thinking organization
as Erytech,” said Christian Hebenstreit, Medidata’s managing director of
the EMEA region. “With our scalable and configurable cloud technology
platform, Erytech has the ability to conduct more informed clinical
trials, enabling its researchers to significantly advance treatment
options for patients across Europe and around the world. We look forward
to supporting Erytech’s R&D efforts as they continue to tackle some of
today’s most difficult-to-treat diseases.”

Connect with Medidata

• Read our blog, Geeks
  Talk Clinical
• Tweet this: .@Medidata
  & French #biopharma @ERYTECH_PHARMA collaborate to drive cutting-edge
  research for #cancer & #RareDisease http://ow.ly/ONQp3067Ahl
• Follow us on Twitter: @Medidata
• Find us on LinkedIn

About Medidata

Medidata
is reinventing global drug development by creating the industry’s
leading cloud-based solutions for clinical research. Through our
advanced applications and intelligent data analytics, Medidata helps
advance the scientific goals of life sciences customers worldwide,
including nearly 800 global pharmaceutical companies, innovative
biotech, diagnostic and device firms, leading academic medical centers,
and contract research organizations.

The Medidata Clinical Cloud^® brings a new level of quality
and efficiency to clinical trials that empower our customers to make
more informed decisions earlier and faster. Our unparalleled clinical
trial data assets provide deep insights that pave the way for future
growth. The Medidata Clinical Cloud is the primary technology solution
powering clinical trials for 17 of the world’s top 25 global
pharmaceutical companies, from study design and planning through
execution, management and reporting.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161114005412/en/